Identification of an alternative polyadenylation site in the human C3b/C4b receptor (complement receptor type 1) transcriptional unit and prediction of a secreted form of complement receptor type 1

doi:10.1084/jem.168.4.1255

This Article

	Full Text (PDF, 1118K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Hourcade, D.
	Articles by Holers, V. M.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Hourcade, D.
	Articles by Holers, V. M.


Social Bookmarking

	What's this?

ARTICLES

Identification of an alternative polyadenylation site in the human C3b/C4b receptor (complement receptor type 1) transcriptional unit and prediction of a secreted form of complement receptor type 1

D Hourcade, DR Miesner, JP Atkinson and VM Holers
Howard Hughes Medical Institute Laboratories, St. Louis, Missouri.

The human C3b/C4b receptor or complement receptor type one (CR1) is an approximately 200-kD single chain membrane glycoprotein of human peripheral blood cells that mediates the binding, processing, and transport of C3b-bearing immune complexes and regulates the activity of the complement cascade. Analysis of partial cDNA clones has shown that the COOH terminus is composed predominantly of three tandemly repeated regions of 450 amino acids each (15). In this report, we present a cDNA sequence that encodes the NH2 terminus of CR1. It appears to have been derived from an alternatively processed transcript, caused by polyadenylation occurring at a site within an intron in the CR1 transcriptional unit. The resulting truncated messenger carries an open reading frame that would produce a short, secreted CR1 form. We present genomic sequences and Northern blots which support this hypothesis and we propose that the NH2-terminal end of CR1 is a likely location for active sites. In addition, we report evidence for a CR1-like sequence in the human genome and we present a model for the organization of CR1.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Facebook Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

This article has been cited by other articles:

Krych-Goldberg, M., Hauhart, R. E., Porzukowiak, T., Atkinson, J. P. (2005). Synergy between Two Active Sites of Human Complement Receptor Type 1 (CD35) in Complement Regulation: Implications for the Structure of the Classical Pathway C3 Convertase and Generation of More Potent Inhibitors. J. Immunol. 175: 4528-4535 [Abstract] [Full Text]
Soares, D. C., Gerloff, D. L., Syme, N. R., Coulson, A. F.W., Parkinson, J., Barlow, P. N. (2005). Large-scale modelling as a route to multiple surface comparisons of the CCP module family. Protein Eng Des Sel 18: 379-388 [Abstract] [Full Text]
Clemenza, L., Isenman, D. E. (2004). The C4A and C4B Isotypic Forms of Human Complement Fragment C4b Have the Same Intrinsic Affinity for Complement Receptor 1 (CR1/CD35). J. Immunol. 172: 1670-1680 [Abstract] [Full Text]
Yazdanbakhsh, K., Kang, S., Tamasauskas, D., Sung, D., Scaradavou, A. (2003). Complement receptor 1 inhibitors for prevention of immune-mediated red cell destruction: potential use in transfusion therapy. Blood 101: 5046-5052 [Abstract] [Full Text]
Lanteri, M., Giordanengo, V., Vidal, F., Gaudray, P., Lefebvre, J.-C. (2002). A complete {alpha}1,3-galactosyltransferase gene is present in the human genome and partially transcribed. Glycobiology 12: 785-792 [Abstract] [Full Text]
Xiang, L., Rundles, J. R., Hamilton, D. R., Wilson, J. G. (1999). Quantitative Alleles of CR1: Coding Sequence Analysis and Comparison of Haplotypes in Two Ethnic Groups. J. Immunol. 163: 4939-4945 [Abstract] [Full Text]
Krych-Goldberg, M., Hauhart, R. E., Subramanian, V. B., Yurcisin, B. M. II, Crimmins, D. L., Hourcade, D. E., Atkinson, J. P. (1999). Decay Accelerating Activity of Complement Receptor Type 1 (CD35). TWO ACTIVE SITES ARE REQUIRED FOR DISSOCIATING C5 CONVERTASES. J. Biol. Chem. 274: 31160-31168 [Abstract] [Full Text]
Krych, M., Hauhart, R., Atkinson, J. P. (1998). Structure-Function Analysis of the Active Sites of Complement Receptor Type 1. J. Biol. Chem. 273: 8623-8629 [Abstract] [Full Text]
Makrides, S. C. (1998). Therapeutic Inhibition of the Complement System. Pharmacol. Rev. 50: 59-88 [Abstract] [Full Text]
Ancian, P., Lambeau, G�r., Matt�i, M.-G.�v., Lazdunski, M. (1995). The Human 180-kDa Receptor for Secretory Phospholipases A[IMAGE]. J. Biol. Chem. 270: 8963-8970 [Abstract] [Full Text]